Drug Discovery Featured Articles & Applications

  1. FDA Leading The Decline Of Animal Testing 7/16/2025

    The gold standard practice of conducting animal studies for evaluating toxicity, pharmacodynamics, and immunogenicity is being challenged by innovative alternatives – New Approach Methods (NAMs).

  2. From Discovery To Delivery: Accelerating The Path Forward For Gene Therapies 7/11/2025

    We caught up with Lexeo Therapeutics’ Manny Otero, Ph.D., and Sandi See Tai, MD, to explore strategies to advance gene therapies.

  3. The Evolving Landscape Of Drug Discovery Services 7/11/2025

    Pharma and biotech companies are set to pursue partnerships with drug discovery service providers at an increased rate in the years ahead. And it’s not just small and emerging drug companies; it’s also Big Pharma.

  4. TYK2 Inhibition Emerges As A Next-Gen Strategy To Treat PsA 7/10/2025

    The treatment landscape for psoriatic arthritis (PsA) is evolving rapidly, with data presented at EULAR 2025 signaling a new chapter in disease management with the emergence of a selective tyrosine kinase 2 (TYK2) inhibitor.

  5. Multi-Indication Strategies Reshape Immunology's R&D Strategy 7/10/2025

    A clear trend at EULAR 2025 emerged across presentations and pipelines: leading biopharma players are increasingly embracing multi-indication strategies, designing assets to work across dermatology, rheumatology, and gastroenterology indications.

  6. Immunology's Next Frontier: High-Risk, High-Reward Innovations From EULAR 2025 7/10/2025

    The 2025 European Congress of Rheumatology (EULAR) showcased a shift in immunology, highlighting a convergence of next-generation mechanisms and novel therapeutic modalities. Of note is the emergence of cell therapies as a treatment strategy.

  7. New Regulatory Considerations For Animal Testing And The Consequences For Drug Product Formulation Development 7/3/2025

    The U.S. is experiencing a shift in the regulatory environment for animal testing, driven by the evolving use of AI. This impacts the formulation development approach for new drugs in the non-clinical phase. 

  8. From Undruggable To Druggable: The Science Reshaping Small Molecule Discovery 7/1/2025

    For decades, most biologically validated disease-relevant protein targets have remained chemically inaccessible, thereby resisting conventional small molecule approaches. But now, a new wave of scientific innovation is paving a way forward.

  9. Five Takeaways from BIO 2025 and Why You Should Stay Tuned 6/26/2025

    New chief editor of Drug Discovery Online shares insights from BIO 2025’s global biotech gathering and spotlights the impacts to early-stage drug research.

  10. From Matrix To Medicine: New Frontiers In Treating Pulmonary Fibrosis And PH 6/25/2025

    Halo Biosciences is building a pipeline based on novel insights into how extracellular matrix dysregulation drives disease. We caught up with its leaders to discuss their approach to drug targeting and early development.